Merck (NYSE:MRK) shares snaps six straight sessions of gains, as the stock closed 2.2% lower at $89.38 on Wednesday.

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Merck (NYSE:MRK) shares were on track to snap six straight sessions of gains on Wednesday, as the stock fell 2.8% at $88.87 ...

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The update was delivered at the Keystone Symposia ‘Human Microbiome: Diversity, Selection and Adaptation’ held 18-21 February ...

Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major pathological response - SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE NEWSWIR ...

A little-known Chinese company has made a drug that beats the world's biggest-selling medicine, said a CNN report on ...

The US Food and Drug Administration has accepted for priority review the supplemental biologics license application for pembrolizumab (Keytruda) to treat patients with resectable, locally advanced ...

Gene's lead asset shows high complete response rates in BCG-unresponsive NMIBC patients. Click here to read why ENGN stock is ...

Trial to begin enrolling in April; expected primary completion in mid-2027 -- Primary study endpoint of rate of major pathological response ...

As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...

大陆新创公司DeepSeek近期推出成本低、效能堪比主流的AI模型，大陆除了在科技领域发展，在生物科技也强势崛起，美国电视新闻CNN报导，大陆一家成立近十年、名不见经传的公司康方生物（Akeso），靠着新型肺癌药物震撼生物科技业界。